Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
Anemia remains the principal management challenge for patients with lower risk Myelodysplastic Syndromes (MDS). Despite appropriate cytokine production and cellular receptor display, erythropoietin receptor (EpoR) signaling is impaired. We reported that EpoR signaling is dependent upon receptor loca...
Main Authors: | McGraw, Kathy L., Basiorka, Ashley A., Johnson, Joseph O., Clark, Justine, Caceres, Gisela, Padron, Eric, Heaton, Ruth, Ozawa, Yukiyasu, Wei, Sheng, Sokol, Lubomir, List, Alan F. |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254997/ |
Similar Items
-
Erythropoietin Receptor Signaling Is Membrane Raft Dependent
by: McGraw, Kathy L., et al.
Published: (2012) -
TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
by: McGraw, Kathy L., et al.
Published: (2015) -
Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation
by: McDaniel, Jessica M., et al.
Published: (2011) -
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
by: Abou Zahr, Abdallah, et al.
Published: (2014) -
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
by: Komrokji, R. S., et al.
Published: (2016)